Interferon retreatment in chronic hepatitis C: Which patients to choose, and what schedule to use

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 6, 1999, Pages 649-653

  Picciotto, Antonino ^a   Campo, Nadia ^a   Brizzolara, Renata ^a   Sinelli, Nicoletta ^a   Torre, Francesco ^a   Cipriani, Antonio Giudici ^b   Ponassi, Irene ^b   Varagona, Giuseppe ^b   Grasso, Alessandro ^c   De Leo, Pasqualina ^c   De Conca, Valerio ^d   Mesiti, Salvatore ^d   Marenco, Giorgio ^b   Menardo, Giorgio ^c   Dodero, Mario ^d   Celle, Guido ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Pietra Ligure Hospital   (Italy)

^c Savona Hospital   (Italy)

^d GALLIERA HOSPITAL   (Italy)

Author keywords

ALT; Chronic hepatitis C; HCV genotype; HCV RNA; Interferon; Long term responders; Non responders; Relapsing responders

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; COHORT ANALYSIS; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL;

EID: 0032805230     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199906000-00011     Document Type: Article

References (30)

1. 1 Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16:649-654.
2. 2 Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105:507-512.
3. 3 Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107:812-817.
4. 4 Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interteron in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997; 26:961-966.
5. 5 Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351:83-87.
6. 6 Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315:1575-1578.
7. 7 Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. Hepatitis Interventíonal Therapy Group. N Engl J Med 1989; 321:1501-1506.
8. 8 Di Bisceglie AM, Martin P, Kassianides C, Lisher-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321:1506-1510.
9. 9 Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13:393-397.
10. 10 Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, et al. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991; 13:327-331.
11. 11 Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L, et al. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol 1993; 17(suppl 3):S123-S126.
12. 12 Bosch O, Tapia L, Quiroga JA, Careno V. An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C. J Hepatol 1993; 17:146-149.
13. 13 Picciotto A, Varagona G, Valle F, Coviello DA, Lapertosa G, Celle G. Interferon therapy in chronic hepatitis C. Evaluation of a low dose maintenance schedule in responder patients. J Hepatol 1993; 17:359-363.
14. 14 Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332:1457-1462.
15. 15 Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon alpha 2b for 60 weeks. Hepatology 1994; 19:280-285.
16. 16 Rabinovitz M, Block G, Finkelstein SD. Alfa-interferon retreatment of patients with chronic hepatitis C. Am J Gastroenterol 1996; 91:1523-1526.
17. 17 Pardo M, Cotonat T, Herrero M, Marriott E, Artillo S, Quiroga JA, et al. Retreatment of chronic hepatitis C virus infection. Lancet 1994; 343:1568-1569.
18. 18 Toyoda H, Nakano S, Takeda I, Kumada T, Sugiyama K, Osada T, et al. Retreatment of chronic hepatitis C with interferon. Am J Gastroenterol 1994; 89:1453-1457.
19. 19 Chemello L, Cavalletto L, Donada C, Bonetti P, Casarin P, Urban F, et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997; 113:1654-1659.
20. 20 Chow WC, Boyer N, Pouteau M, Castelnau C, Martinot-Peignoux M, Martins-Amado V, et al. Re-treatment with interferon alfa of patients with chronic hepatitis C. Hepatology 1998; 27:1144-1148.
21. 21 Weiland O, Zhang YY, Widell A. Serum HCV-RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment. Scand J Infect Dis 1993; 25:25-30.
22. 22 Gerken G, Teuber G, Goergen B, Meyer zum Buschenfelde KH. Interferon-alpha retreatment in chronic hepatitis C. J Hepatol 1995; 22(suppl 1):118-121.
23. 23 Marriott E, Quiroga JA, Carreno V. Retreatment of chronic hepatitis C with interferon-alpha. J Infect Dis 1992; 166:1200-1201.
24. 24 Marcellin P, Pouteau M, Boyer N, Castelnau C, Erlinger S, Benhamou JP. Retreatment with recombinant interferon-alpha in patients with chronic hepatitis C. J Infect Dis 1993; 167:780-781.
25. 25 Kakumu S, Yoshioka K. Retreatment with interferon in patients with chronic hepatitis C. J Hepatol 1994; 21:483.
26. 26 Picciotto A, Brizzolara R, Campo N, Lapertosa G, Cells G. Long-term interferon alfa-2b retreatmont of relapsing patients with chronic hepatitis C. J Hepatol 1997; 26:447-448.
27. 27 Payen JL, Izopet J, Galindo V, Zarski JP, Seigneurin JM, Dussaix E, et al. A comparison of three interferon alfa-2b regimens for retreatment of patients with chronic hepatitis C with prior complete response followed by relapse: a controlled, randomized trial [Abstract]. Hepatology 1996; 24:273A.
28. 28 Chow WC, Marcellin P, Boyer N, Pouteau M, Castelnau C, Degos F, et al. Interferon retreatment in chronic hepatitis C (CHC) patients after a standard course of interferon therapy [Abstract]. Hepatology 1996; 24:274A.
29. 29 Han JH, Shjamala V, Richman KH, Brauer MJ, Irvine B, Urdea MS, et al. Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end. Proc Natl Acad Sci USA 1991; 88:1711-1715.
30. 30 Ishak K, Baptists A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.